TcLand Expression - Product Pipeline Analysis, 2017 Update

  • ID: 4372820
  • Company Profile
  • 22 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Aptys Pharmaceuticals SAS
  • SERB SAS
  • MORE
Summary

TcLand Expression (TcLand) is a developer of companion diagnostics in immune mediated disorders and biomarkers in solid organ transplantation. The company develops companion diagnostics based on its gene expression biomarkers platform. Its research and development platform develops and validates invasive multi-genes molecular diagnostic blood tests. TcLand’s clinical development programs include RA-INF-Dx Test, IMD Dx2, IMD Dx3 and L-TolX test. The company also offers liver transplantation and rheumatoid arthritis services. It partners with pharma and biotech companies for the development of companion diagnostics. TcLand is headquartered in Mulhouse, France.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company TcLand Expression
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aptys Pharmaceuticals SAS
  • SERB SAS
  • MORE
  • TcLand Expression Company Overview
  • TcLand Expression Company Snapshot
  • TcLand Expression Pipeline Products and Ongoing Clinical Trials Overview
  • TcLand Expression - Pipeline Analysis Overview
  • TcLand Expression - Key Facts
  • TcLand Expression - Major Products and Services
  • TcLand Expression Pipeline Products by Development Stage
  • TcLand Expression Pipeline Products Overview
  • IMD Dx2
  • IMD Dx2 Product Overview
  • IMD Dx3
  • IMD Dx3 Product Overview
  • L-TolX
  • L-TolX Product Overview
  • RA-INF-Dx
  • RA-INF-Dx Product Overview
  • TcLand Expression - Key Competitors
  • TcLand Expression - Key Employees
  • TcLand Expression - Locations And Subsidiaries
  • Head Office
  • Recent Developments
  • TcLand Expression, Recent Developments
  • Jun 17, 2011: TcLand Expression Receives €1.2m From Oseo And ERDF To Support Project In Personalized Medicine
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • TcLand Expression Pipeline Products and Ongoing Clinical Trials Overview
  • TcLand Expression Pipeline Products by Equipment Type
  • TcLand Expression Pipeline Products by Indication
  • TcLand Expression, Key Facts
  • TcLand Expression, Major Products and Services
  • TcLand Expression Number of Pipeline Products by Development Stage
  • TcLand Expression Pipeline Products Summary by Development Stage
  • IMD Dx2 - Product Status
  • IMD Dx2 - Product Description
  • IMD Dx3 - Product Status
  • IMD Dx3 - Product Description
  • L-TolX - Product Status
  • L-TolX - Product Description
  • RA-INF-Dx - Product Status
  • RA-INF-Dx - Product Description
  • TcLand Expression, Key Employees
  • Glossary
List of Figures
  • TcLand Expression Pipeline Products by Equipment Type
  • TcLand Expression Pipeline Products by Development Stage
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • SERB SAS
  • Aquitaine Pharm International
  • Aptys Pharmaceuticals SAS
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll